New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
08:16 EDTBCLIBrainStorm Cell announces presentation of Phase IIa ALS trial data
BrainStorm Cell announced that interim results from the company's Phase IIa ALS trial conducted at Hadassah Medical Center were presented at the Joint Congress of European Neurology. The positive safety and preliminary efficacy results observed in this study are consistent with results observed in the company's previous Phase I/II trial. Between these two studies, a total of 26 patients have been treated with NurOwn, BrainStorm's stem cell therapy candidate for ALS. The company said, "We are very satisfied with the results observed so far in these two studies. The fact that some of the patients actually demonstrated clinical improvement surpassed our expectations of achieving stabilization or reduced rate of decline. We look forward to the completion of this trial and to building on these results in our double-blind, placebo controlled, multi-center study currently being launched in the USA."
News For BCLI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 26, 2015
10:50 EDTBCLIBrainStorm management to meet with Maxim
Subscribe for More Information
08:27 EDTBCLIBrainStorm reports Q4 EPS (18c), one estimate (15c)
Subscribe for More Information
March 25, 2015
07:16 EDTBCLIPiper Jaffray and the Alliance for Regenerative Medicine co-host conference
3rd Annual Regenerative Medicine Investor Day is being held in New York on March 25 with webcasted company presentations to begin at 8 am; not all company presentations may be webcasted. Webcast Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use